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Abstract
Aim: To synthesize cRGDf K peptide conjugated poly(γ-glutamic acid)-phenylalanine nanoparticles to
improve the therapeutic efficacy of camptothecin (CPT) against glioblastoma multiforme.
Methods: Peptide-conjugated, drug-loaded nanoparticles (cRGDf K-conjugated camptothecin-loaded PGA-
PA nanoparticles [RCPN]) were prepared and physico-chemically characterized using different techniques.
Nanoparticles were evaluated for in vitro anticancer activity, cellular uptake, induction of apoptosis and
wound healing cell migration against U87MG human glioblastoma cells.
Results: RCPN, with a particle size of < 100 nm and 65% CPT encapsulation efficiency, exhibited a dose-and
time-dependent cytotoxicity to glioblastoma cells. Compared with native CPT or unconjugated
nanoparticles, RCPN induced apoptosis, increased reactive oxygen species generation and inhibited U87MG
cell migration.
Conclusion: cRGDf K-mediated and amphiphilic copolymer-based nanomedicines represent a new approach
for improved delivery of anticancer drugs to and treatment of glioblastoma multiforme.
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Peptide grafted and self-assembled poly(γ-glutamic acid)-
phenylalanine nanoparticles targeting camptothecin to glioma  
 
Abstract 
Aim: To synthesize cRGDfK peptide conjugated poly(γ-glutamic acid)-phenylalanine 
nanoparticles to improve the therapeutic efficacy of camptothecin (CPT) against glioblastoma 
multiforme (GBM). Methods: Peptide-conjugated, drug-loaded nanoparticles (RCPN) were 
prepared and physico-chemically characterized using different techniques. Nanoparticles 
were evaluated for in vitro anticancer activity, cellular uptake, induction of apoptosis and 
wound healing cell migration against U87MG human glioblastoma cells. Results: RCPN, 
with a particle size of <100 nm and 65% CPT encapsulation efficiency, exhibited a dose- and 
time-dependent cytotoxicity to glioblastoma cells. Compared to native CPT or unconjugated 
nanoparticles, RCPN induced apoptosis, increased reactive oxygen species generation and 
inhibited U87MG cell migration. Conclusion: cRGDfK-mediated and amphiphilic 
copolymer based nanomedicines represents a new approach for improved delivery of 
anticancer drugs to and treatment of GBM. 
 
Keywords: Glioblastoma multiforme; camptothecin; poly(γ-glutamic acid); phenylalanine; 
cRGDfK; anti-cancer activity 
 
Abbreviations: Carboxy-DCFDA: 5(6)-Carboxy-2′,7′-dichlorofluorescein diacetate; CPN: 
Camptothecin loaded PGA-PA nanoparticles; CPT: Camptothecin; cRGDfK: Cyclo(Arg-Gly-
Asp-D-Phe-Lys); DCFDA: Carboxy-2', 7'-dichlorofluorescein diacetate; DMEM: Dulbecco’s 
modified eagle medium; DMSO: Dimethyl sulfoxide; EDC: 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide; FBS: Fetal bovine serum; GBM: Glioblastoma 
2 
 
multiforme; IC50: half-maximal inhibitory concentration; MTT, 3-(4, 5- dimethylthiazol-2-
yl)-2, 5-diphenyl tetrazolium bromide; NHS: N-hydroxysuccinimide; PA: Phenyl alanine; 
PAE: Phenyl alanine ester; γ-PGA: Poly(γ-glutamic) acid; PGA-PA: Poly(γ-glutamic acid)-
phenyl alanine conjugate; RCPN:  cRGDfK conjugated and Camptothecin loaded PGA-PA 
nanoparticles; ROS: Reactive oxygen species; RPN: Rhodamine-b loaded PGA-PA 
nanoparticles; RRPN: cRGDfK peptide conjugated RPN; UPLC: Ultra performance liquid 
chromatography; VEGF: Vascular endothelial growth factor. 
  
3 
 
Introduction 
Glioblastoma multiforme (GBM) is the most common type of brain tumor, accounting for 
29% of primary brain cancers.
1 
Among all types of cancer, GBM is the most difficult to treat 
as it localizes in brain that has limited capacity to repair itself. In addition, GBM tumors show 
inherent resistance to conventional therapy and have poor blood supply; thus drug delivery is 
inhibited.
2 
Tumor infiltration into brain tissue makes it very difficult to treat GBM with 
conventional surgical removal. Because of this diffusive invasion, recurrence from residual 
tumors is also common.
3 
Therefore, multiple therapies are needed to treat GBM. Currently, 
the best approach for the management of GBM is initial surgery followed by radiation and 
adjuvant chemotherapy.
4, 5 
Chemotherapy plays an important role in the treatment of GBM 
especially in recurrent GB, however, the blood brain barrier, drug resistance and systemic 
toxicity of anticancer drugs decrease the therapeutic efficacy of available agents.
6
 
In recent years, ligand-mediated, targeted drug delivery has shown promise in effective 
delivery of drugs to brain tumors.
7, 8 
In ligand-mediated drug delivery, nanoparticle surfaces 
are modified with a ligand that selectively binds to specific receptors on cancer cells. 
Receptors for molecules such as glucose,
9 
folate,
10 
human epidermal growth factor,
11 
lectins,
12, 13 
lactoferrin,
14 
transferrin
15, 16 
and integrin have been studied as a potential targets 
for chemotherapy to treat brain cancer.
17-24 
Peptides, such as TAT peptide, that can penetrate 
cells have also been used to target brain tumor.
25, 26
 However, these cell-penetrating peptides 
may also enhance the penetration of nanocarriers into normal cells resulting in toxicity. αvβ3 
integrins are over-expressed on endothelial and tumor cells in both primary and recurrent 
GBM.
27-29
 RGD-based peptides have high affinity towards αvβ3 integrins and cyclic RGD 
peptides have been used successfully for in vivo imaging, magnetic resonance imaging and 
drug delivery to GBM.
30-32 
Kim et al. used RGD-conjugated peptide and radioactive iodine-
labelled gold nanoparticles for imaging of tumor sites.
33 
Jin et al. synthesised cRGDyK 
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conjugated paramagnetic nanoprobes for the imaging of αvβ3 overexpressing U87MG tumor 
xenografts.
34 
In a previous study, we demonstrated the targeting of cRGDfK-grafted 
nanomicelles to DU145 prostate cancer cells and to SKOV-3 ovarian cancer cells that 
overexpress integrin αvβ3.
35, 36
 
Here, we synthesized cRGDfK conjugated poly(γ-glutamic) acid nanoparticles for the 
selective delivery of camptothecin (CPT) to GBM. γ-PGA is a microbially produced and non-
toxic biopolymer. The degraded product of γ-PGA is a natural amino acid i.e. glutamic acid. 
Due to excellent biocompatibility and biodegradation, it has been explored for a wide range 
of biomedical applications including drug delivery.
37
 High drug loading capacity, stability in 
biological fluids and controlled release properties are specific advantages of polymeric 
nanoparticles.
38
 However, native γ-PGA is not suitable as drug delivery carrier because of 
aqueous solubility. Therefore, it was conjugated with hydrophobic phenyl alanine to produce 
an amphiphilic copolymer which spontaneously forms nanoparticles in aqueous solution. 
CPT is a natural quinone alkaloid that has high efficacy against malignant gliomas.
39-41 
CPT 
binds to the topoisomerase I-DNA complex during cell division, stabilizing the complex and 
therefore preventing the replication processes.
42 
Moreover, CPT acts only in the S-phase of 
cell cycle. As cancer cells have longer S-phase compared to normal healthy cells, S-phase 
selectivity makes CPT a suitable drug candidate in the development of a targeted drug 
delivery system for GBM.
43
 Poor penetration across the blood brain barrier, dose-limiting 
toxicity and rapid hydrolysis at physiological pH are the major inherent problems with native 
CPT.
44
 Therefore, encapsulation of CPT in cRGDfK conjugated poly(γ-glutamic) acid 
nanoparticles may overcome these drawbacks of CPT.  
 
Experimental section 
Materials  
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cRGDfK was purchased from Peptide International (Kentucky, USA). CPT, Poly(γ-glutamic) 
acid (γ-PGA) molecular weight ~50,000-100,000 Da, phenylalanine (PA), 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC), N-hydroxysuccinimide (NHS), Dulbecco’s 
modified eagle medium (DMEM), trypsin–EDTA, penicillin, streptomycin, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), dimethyl sulfoxide (DMSO) 
and propidium iodide (PI) were purchased from Sigma Aldrich (AUS). Fetal bovine serum 
(FBS) was purchased from Gibco, USA. Carboxy-2',7'-dichlorofluorescein diacetate 
(DCFDA) and Hoechst 33342 were purchased from Life Technologies Australia Pvt Ltd. 
(AUS). 
 
Synthesis and characterization of phenylalanine ester (PAE) 
Thionyl chloride (0.87 mL, 12.1 mM) was added to a solution of phenylalanine (1 g, 6.05 
mM) in methanol. The reaction was continued for 30 min in an ice-bath and then stirred for 
24 h at room temperature. After completion of the reaction (as monitored by thin layer 
chromatography), an excess of thionyl chloride was removed under reduced pressure using a 
rota-evaporator. Phenylalanine ester (PAE) was obtained as a white solid powder and 
characterized by 
1
H NMR and FTIR analysis. 
 
Synthesis and characterization of poly(γ-glutamic acid)-phenylalanine (PGA-PA) 
conjugate 
PGA-PA conjugate was synthesized as described previously.
45 
Briefly, 200 mg γ-PGA was 
dissolved in 30 mL sodium bicarbonate solution (50 mM) and placed in an ice-bath on a 
magnetic stirrer. EDC (300 mg) was then added and stirred for 1 h. Thereafter, PAE (310 mg) 
was added to the reaction mixture and stirred overnight. PGA-PA conjugate was purified by 
dialysis against deionized water for three days, freeze-dried and stored. The conjugate was 
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characterized by proton nuclear magnetic resonance (
1
HNMR) and Fourier transform infrared 
(FTIR) analysis. 
 
Preparation of CPT loaded PGA-PA nanoparticles (CPN) 
For the preparation of CPT loaded PGA-PA nanoparticles (CPN), CPT and PGA-PA were 
dissolved in DMSO and mixed with surfactant solution (1.5% w/v Tween 80). The dispersion 
was dialyzed against deionized water for 24 h and then centrifuged for 30 min at 15,000 rpm. 
The nanoparticle pellet was redispersed in distilled water and again centrifuged to remove 
free or non-encapsulated drug. Drug loaded nanoparticles were freeze-dried and stored at 4 
°C. The amount of drug in the supernatant was determined using an Ultra performance liquid 
chromatography (UPLC) system (Waters Acquity UPLC, Aus). A reversed-phase column 
(Acquity C18, 1.7 µm, 2.5 × 50 mm) was used at 30 °C. The mobile phase was composed of 
methanol and water (45:55). The flow rate was set at 0.45 mL/min and the detection 
wavelength was 256 nm. 
 
Characterization of nanoparticles 
Particle size and zeta potential were determined by photon correlation spectroscopy using a 
Zetasizer Nano-ZS (Malvern instrument Ltd., Malvern, UK). The surface morphology of 
nanoparticles was studied by transmission electron microscopy (TEM). Differential scanning 
calorimetry of native CPT, PGA-PA, a physical mixture of CPT and PGA-PA, and CPN were 
carried out on aDSC-Q100 (TA Instruments, USA). The samples were scanned from 25 to 
300 °C at a speed of 10 °C/min under nitrogen environment. Powder X-ray diffraction 
patterns of CPT and CPN were obtained in the range of 5–65º using an X-ray Diffractometer 
(D8 Advance, Bruker, Germany), equipped with a graphite crystal monochromator (CuKa). 
The instrument was set at a voltage 40 KV and a current of 40 mA.  
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Bioconjugation of cRGDfK to CPN (RCPN) 
Nanoparticles (50 mg) were dispersed in 5 mL phosphate buffer saline and incubated with 
EDC (35 mg) and NHS (21 mg). After 30 min, cRGDfK was added and stirred for 4 h at 
room temperature. cRGDfK conjugated nanoparticles were obtained by centrifugation and 
washed three times with PBS. The supernatant was used to determine the amount of 
unconjugated cRGDfK. 
 
In vitro drug release studies 
The release of CPT from nanoparticles was studied by modified dialysis method. Phosphate 
buffer saline pH 7.4 and sodium acetate buffer pH 5 were used as release media. 
Nanoparticles, equivalent to 0.5 mg CPT, were dispersed in 1 mL of release media and placed 
in a dialysis bag. This dialysis bag was further placed in a beaker containing 50 mL of release 
media maintained at 37 °C and stirred at 100 rpm. At the end of each time point, 1 mL  
DMSO was added to the dialysis bag and drug content was measured. The % drug release 
(DR) was determined as follows: % DR = {(DI-DF)/DI} × 100 
where DI = Initial amount of drug present in nanoparticles added in the dialysis bag, and DF 
= Final amount of drug present in the nanoparticles after a time interval. 
 
Cell culture 
Mycoplasma-free U87MG human glioblastoma cells were obtained from Peter MacCallum 
Cancer Institute, Australia. Cells were grown in DMEM media supplemented with 10% FBS, 
2 mM glutamine, penicillin (100 U/mL), and streptomycin (0.1 mg/mL). Cells were 
cultivated under standard conditions at 37 °C in a humidified atmosphere (85% relative 
humidity) containing 5% CO2. 
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In vitro cytotoxicity assay 
The cytotoxicity of the pure CPT and drug-loaded nanoparticles was evaluated by the MTT 
assay. U87MG cells (5×10
3
) were seeded in 96-well plates and incubated for 24 h. Cells were 
then treated with CPT, CPN or RCPN (1-400 ng/mL) for 24 and 48 h at 37 °C. Untreated 
cells served as controls. After incubation, 100 µL DMEM medium containing MTT reagent 
(0.5 mg/mL) was added to each well. The plate was then incubated at 37 °C for 4 h. The 
violet-colour formazan crystals were dissolved in 150 µL DMSO. Absorbance was measured 
at 570 nm using a microplate reader and the percentage viability of cells was calculated as the 
ratio of absorbance of sample to control wells.  
 
Cellular uptake of nanoparticles in cells 
Comparative uptake of unconjugated (RPN) and cRGDfK-conjugated nanoparticles (RRPN) 
was studied using Rhodamine-b loaded nanoparticles, which were prepared in manners 
similar to those for CPN and RCPN, except that instead of CPT drug, Rhodamine-b was 
loaded in these nanoparticles. Cells were incubated with RPN and RRPN for 2 h at 37 °C. 
Cells were washed twice with PBS and incubated with 5 µg/mL Hoechst 33342 to stain 
nuclei. After 30 min incubation, cells were washed with PBS and observed by fluorescence 
microscopy. To confirm the receptor-dependent binding of RRPN, cells were incubated with 
an excess of cRGDfK peptide (100 µg/mL) 1 h prior to incubation with targeted 
nanoparticles RRPN. 
 
Estimation of apoptosis  
Apoptosis in cells treated with CPT, CPN and RCPN was estimated by an Annexin V PE 
Cys5.5 and PI assays. Cells were seeded in 6-well plates at 1×10
6
 cells/well and incubated for 
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24 h to allow adherence to the plate surface. Cells were treated with 20 ng/mL CPT, CPN or 
RCPN for 24 h. The cells were then collected, washed with PBS, stained according to the 
manufacturer’s instructions and analyzed by BD FACS Canto™ II.  
 
Nuclear staining with Hoechst 33242 
Nuclear morphology of CPT, CPN or RCPN treated cells was studied by Hoechst 33342 
staining. Hoechst 33342 is a DNA specific fluorescent dye used to study nuclear morphology. 
U87MG cells (1×10
5
) were seeded in 24-well microplates and incubated overnight. Cells 
were then incubated with free drug or nanoparticles (CPT concentration, 20 ng/mL). After 
washing with PBS, cells were stained with Hoechst 33342 (5 µg/mL) at 37 °C for 30 min in 
the dark. Cells were washed again with PBS and observed under afluorescence microscope. 
% Apoptosis was determined as follows: 
% Apoptosis = (Number of apoptotic cells/Total number of cells) × 100 
 
Measurement of reactive oxygen species (ROS) 
U87MG cells were seeded at a density of 1×10
5
 cells per well in 24-well plates and incubated 
for 24 h at 37 °C. Cells were then treated with CPT formulations equivalent to 20 ng/mL CPT 
for 24 h, washed twice with PBS and fixed with 4% paraformaldehyde for 10 min. After 
washing two times with PBS, cells were incubated with DCFDA (10 µM) for 30 min in the 
dark. Cells were finally washed with PBS and observed using a fluorescence microscope 
(Nikon, Japan).  
For quantitative estimation of ROS, cells were harvested using 0.25% trypsin-EDTA 
and washed with PBS. Cell counts were adjusted for all formulations. Cells were incubated 
with DCFDA (10 µM) for 30 min in the dark and fluorescence intensity was measured at 
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excitation and emission wavelengths of 495 and 520 nm, respectively, using a Hitachi F-3010 
spectrofluorometer. 
 
Wound healing scratch assay 
The effect of CPT formulations on wound healing or the migration of cells was analyzed by 
the scratch-wound healing assay, with slight modification as reported previously.
46 
U87MG 
cells were cultured to form an approximate80% confluent monolayer. The monolayers were 
scratched with a sterile 200-µL pipette tip to form a “wound”. Cells were washed twice with 
PBS to remove cellular debris. Cells were then incubated with CPT, CPN or RCPN in serum-
free media for 24 h. Images were captured at 0 and 24 h to monitor the migration of cells into 
the wound area using a photomicroscope (Nikon, Japan). The % of wound closure was 
determined by measuring the wound area using Image J analysis software. 
 
Statistical analysis 
All studies were performed in triplicate and results are expressed as Mean ± SD (standard 
deviation). Statistical significance was determined using the student t-test for two groups and 
one-way ANOVA for multiple groups. Statistical significance was assumed at p < 0.05. 
 
Results  
Synthesis and characterization of PGA-PA conjugates 
For the synthesis of poly(γ-glutamic acid)-phenylalanine conjugate (PGA-PA) firstly, 
phenylalanine (PA) was converted to phenylalanine ester (PAE). Esterified PA was 
conjugated to γ-PGA through a carbodiimide reaction (Figure S1) and conjugation efficiency 
was determined by NMR analysis (Figure S2). The peaks corresponding to the methylene 
protons (δ 2.1) of γ-PGA and the aromatic protons of the benzene ring (δ 7.3) of PA were 
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compared. The conjugation efficiency was 52.9%. The PGA-PA conjugate was also 
confirmed by FTIR analysis (Figure S3). The FTIR spectrum of PA showed two 
characteristic N-H stretching vibration bands at 3078 cm
-1
 and 3030 cm
-1
. Bands 
corresponding to asymmetric and symmetric stretching vibrations of the carboxylic group 
(COO
-
) were observed at 1557 cm
-1
 and 1409 cm
-1
, respectively. The stretching vibration 
band of benzene appeared at 745 cm
-1
. After esterification of the carboxylic group of PA, a 
sharp band was observed at 1736 cm
-1 
indicative of C=O stretching of the ester bond. The 
FTIR spectrum of γ-PGA showed bands at 3263 cm
-1
 (NH stretching), 1644 cm
-1
 (amide I) 
and 1551 cm
-1
 (amide II). γ-PGA was conjugated to esterified PA through amide coupling 
between the amine group of PA and amine group of γ-PGA. The FTIR spectrum of the PGA-
PA conjugate showed a shift in the γ-PGA peaks (3263 to 3278, 1644 to 1648 and 1551 to 
1544 cm
-1
). A new peak at 746 cm
-1 
corresponding to the benzene ring of PA confirmed 
successful conjugation of PA to PGA. 
Characterization of nanoparticles 
BPN (blank nanoparticles without the drug) and CPN were synthesized by the dialysis 
method. Physicochemical parameters of different nanoparticles are presented in Table 1. BPN 
showed particle size of 66 nm with very low polydispersity of 0.08 and high negative zeta 
potential of −30.9 mV. After CPT loading, the nanoparticle size was increased slightly to 
81.6 nm without a significant change in polydispersity (0.09) and zeta potential (−29.7 mV). 
cRGDfK grafted nanoparticles were of 89.7 nm in size and −16.7 mV zeta potential (Table 
1). A decrease in negative zeta potential of RCPN confirmed the conjugation of cRGDfK on 
the surface of CPN. Morphology of nanoparticles was studied using transmission electron 
microscopy (TEM) analysis (Figure S3). The size of the nanoparticles after drug loading and 
cRGDfK conjugation was less than 100 nm (Figure 1a); an ideal size for a nanocarrier system 
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to cross the blood-brain barrier.
8 
RCPN were also characterized by FTIR analysis (Figure 1b). 
% encapsulation efficiency for CPN and RCPN was 68.4% and 65.2%, respectively. 
Drug loaded nanoparticles were also characterized for differential scanning calorimetry 
(DSC) and X-ray diffraction (XRD) analysis. DSC spectra of CPT and CPN are presented in 
Figure 1c.  The DSC spectra of CPT showed a sharp endothermic peak at 268 °C 
corresponding to the melting point. However, this peak was not observed in CPT-loaded 
nanoparticles (CPN). The absence of a CPT peak may be due to its amorphous or disordered 
crystalline state or to solid solution in polymeric matrix of nanoparticles. 
Figure 1d demonstrates the XRD patterns of pure CPT, PGA-PA conjugate, a physical 
mixture of CPT and PGA-PA, and CPN. The XRD pattern of raw CPT showed characteristic 
high-intensity diffraction peaks at diffraction angles of 2θ 6.2°, 8.5°, 11.5°, 12.1°, 13.6°, 
17.8° and 25° suggesting the crystalline nature of the drug.
47 
Due to its amorphous nature, the 
XRD patterns of PGA-PA did not show any sharp peaks. We observed all the characteristic 
peaks of CPT in the XRD pattern of the physical mixture of CPT and PGA-PA, 
demonstrating a lack of chemical interaction between CPT and PGA-PA. However, owing to 
transformation of CPT from a crystalline to an amorphous phase during nanoparticle 
preparation, the peaks representing CPT were absent in the CPN XRD pattern. 
The release of CPT from nanoparticles was determined by modified dialysis method. 
As CPT is unstable at physiological pH, drug release was indirectly determined by measuring 
the drug present in the nanoparticles. Figure S4 shows that the release of CPT from 
nanoparticles was pH-dependent. After 24, 48 and 72 h, the release of CPT from 
nanoparticles at pH 7.4 was 26%, 33% and 40%, respectively, whereas for the same time 
points, at pH 5 CPT was released 37%, 43% and 54%, respectively. The slow release of drug 
from nanoparticles at physiological pH would help in improved intracellular delivery. 
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Further, comparatively faster release at acidic pH indicates that encapsulated drug will 
release rapidly after reaching the cell organelles (lysosomes and endosomes) where the pH of 
drug remains below 5.5.
48
 It was further observed that CPT was released in a biphasic pattern. 
Initially there was fast release of drug up to 12 h which was sustained up to 72 h. 
Approximately 21% and 29% of encapsulated drug was released from nanoparticles at pH 7.4 
and pH 5, respectively, after 12 h of dialysis. This initial rapid release of drug can be 
explained by the release of drug present in the periphery of the nanoparticles.  
In vitro cytotoxicity 
In order to investigate the anti-proliferation activity of native CPT and CPT loaded 
formulations (CPN and RCPN), cell viability of U87MG human glioblastoma cells was 
determined using the MTT assay. Anticancer activities of pure drug as well as drug-loaded 
nanoparticles depend on both the dose of drug and time of incubation. Therefore, U87MG 
cells were incubated with free CPT, CPN or RCPN, equivalent to 1-400 ng/mL CPT, for 24 
and 48 h. The cell viability of U87MG cells after 24 h and 48 h are shown in Figure 2a and b, 
respectively. All three formulations showed caused a significant decrease in cell viability. 
After 24 h, the cell viability was 99.2%, 77.3%, 63.4% and 34.5% after incubation with blank 
nanoparticles (BPN), CPT, CPN or RCPN, respectively, equivalent to 50 ng/mL CPT. As the 
incubation time was increased, cell viability further decreased. At the same drug 
concentration (50 ng/mL CPT), the observed cell viability was 98.1%, 45.8%, 33.4% and 
20.7%, respectively, after 48 h incubation.  Half-maximal inhibitory concentrations (IC50) for 
the three formulations are presented in Table 2. After 24 h, targeted nanoparticles (RCPN, 
IC50 = 30.46 ng/mL) were more effective than non-targeted nanoparticles (CPN, IC50 = 
168.29 ng/mL) and native CPT (IC50 = 552.21 ng/mL) (p < 0.01). A similar pattern was 
observed after 48 h incubation where the IC50 value of RCPN (11.34 ng/mL) was 2.3 and 5.4 
times lower than CPN (27.05) and CPT (61.78 ng/mL), respectively. The results suggest that 
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RCPN not only inhibits cell growth at higher efficiency than native CPT (p < 0.01) but also 
lowers the minimum effective dose required for cytotoxicity. 
Uptake of nanoparticles by U87MG cells 
Internalization of nanoparticles was studied using Rho-b loaded nanoparticles. Nuclei were 
visualized by Hoechst 33342 staining. Figure 3 shows fluorescence microscopic images of 
U87MG cells after 2 h of incubation with nanoparticles. cRGDfK conjugated and Rho-b 
loaded γ-PGA nanoparticles (RRPN) showed higher intracellular accumulation of Rho-b than 
unconjugated nanoparticles (RPN). The increased uptake of targeted nanoparticles could be 
attributed to the presence of cRGDfK on the surface of nanoparticles. Peptide containing 
RGD moieties have been reported to be taken uptake by U87MG cells more efficiently than 
unconjugated nanoparticles.
49,50
 Therefore, the enhanced cytotoxicity of RCPN formulation 
than CPN can be correlated to the higher uptake of RRPN. To further confirm uptake of 
RRPN through integrin receptors, competitive binding assay was performed. Integrin 
receptors expressed on the surface of U87MG cells were blocked by adding an excess of 
cRGDfK peptide before incubating with RRPN. The fluorescence intensity in these cells was 
significantly lower compared to cells incubated with RRPN alone which suggested that 
RRPN were taken by integrin receptors.  
Analysis of apoptosis  
Evasion of apoptosis by cancer cells is major barrier to cancer treatment.
51 
Apoptosis induced 
by different CPT formulations was studied both qualitatively and quantitatively using 
Hoechst staining (Figure 4a, b). Cells treated with CPT, CPN or RCPN showed fragmented 
nuclei whilst control or untreated cells exhibited intact nuclei (Figure 4a). The percentage of 
apoptotic cells after treatment with RCPN (46.9%) was much higher than with CPN (35.6%) 
and CPT (26.9%) treatment (Figure 4b). Apoptosis was also analysed by annexin Cys5.5/PI 
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assay using a flow cytometer. As shown in Figure 4a, the percentage of live U87MG cells 
was decreased with the three CPT formulations. The percentage of live cells in control, CPT, 
CPN and RCPN was 98.4%, 71.6%, 62.4% and 52.5%, respectively. The ability of the 
different CPT formulations to induce cell death followed the order: RCPN>CPN>CPT 
(Figure 4a). Cells treated with RCPN were more apoptotic compared to those treated with 
native drug and CPN (p < 0.01).  
Intracellular ROS generation 
Anticancer drugs, including CPT, generate ROS.
52-54 
Intracellular reactive oxygen species 
(ROS) generation can be measured using the DCFDA dye. Fluorescent intensity of DCFDA 
is directly related to intracellular ROS levels. In the present study, fluorescence intensity was 
measured both qualitatively and quantitatively (Figure 5a, b). Control, or untreated cells, 
showed less green fluorescence than drug treated cells. Among the three CPT formulations, 
RCPN showed 2.51 and 1.48 times higher fluorescence intensity than CPT and CPN, 
respectively. This may be explained by the enhanced intracellular delivery of CPT by 
targeted nanoparticles.  
Wound-healing assay 
Gliomas exhibit significant angiogenesis that is induced by vascular endothelial growth factor 
(VEGF). VEGF is responsible for the formation of new blood vessels required for tumor 
growth and cell migration.
55,56 
To study the effect of targeted delivery of RCPN on the cell 
migration of U87MG, wound-healing or scratch assays were performed. Cells were observed 
by light microscopy. Figure 6a shows the migration distance observed after 0 and 24 h of 
wound creation. % Closure of wound area observed after 24 h of treatment was 86.3%, 
63.8%, 47.4% and 9.6% for control, CPT, CPN and RCPN, respectively (Figure 6b).  
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Discussion 
GBM is a grade IV astrocytoma arising from glial cells. These tumors show cellular 
heterogeneity and can rapidly invade surrounding tissues. Despite efforts, and multimodal 
aggressive treatments, the median survival time is only about 12 months.
57 
The most common 
problem in the treatment of GBM is ineffective delivery of anticancer drugs to the tumor 
cells. Only low molecular weight (<500 Da) molecules with high lipophilicity can enter the 
central nervous system.
58 
Nanoparticles have potential to the enter central nervous system and 
represent as a promising vehicle for the thernostic applications in cancer treatment. However, 
due to complex particle internalization processes in brain cells, a simple nanoparticle 
formulation is not suitable to treat GBM. Therefore, use of targeting ligands with specificity 
for particular receptors is an ideal approach for the delivery of nanoparticles in GBM. Apart 
from better uptake and enhanced intracellular delivery of encapsulated drug molecules, 
targeted and specific delivery also overcomes the inherent problems of anticancer drugs such 
as non-specific and systemic toxicity and drug resistance.
59
 In this study, we synthesized 
amphiphilic poly(γ-glutamic acid)-phenylalanine conjugate and used this conjugate as a 
biomaterial for the preparation of CPT loaded nanoparticles. For the preparation of targeted 
nanoparticles, cRGDfK was conjugated via the amine group of lysine moieties to free 
carboxylic groups on the surface of drug loaded nanoparticles using a carbodiimide reaction. 
This nanocarrier system was evaluated for anticancer efficacy, cellular uptake and induction 
of apoptosis using U87MG human glioblastoma cells.   
γ-PGA is a water soluble, biodegradable, naturally occurring poly(amino acid) 
composed of glutamic acid molecules linked through the amide bonds between α-amino and 
γ-carboxylic acid groups.
37, 60
 The structure of PGA-PA nanoparticles is a shell type with a 
hydrophobic PA core and an outer hydrophilic cortex of PGA.  Drug loaded nanoparticles 
were prepared by a dialysis method and an optimized nanoparticle formulation was 
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conjugated with cRGDfK peptide to prepare targeted nanoparticles. The size of the 
nanoparticles after drug loading and cRGDfK conjugation was less than 100 nm; an ideal size 
for a nanocarrier system to across the blood-brain barrier.
8 
The aim was to develop receptor-specific nanoparticles to enhance the specificity and 
cellular toxicity of CPT. Cellular uptake of nanoparticles in cancer cells was determined by 
fluorescence microscopy. After 2 h of incubation, peptide conjugated nanoparticles are taken 
up more by the cells and showed higher fluorescence intensity than unconjugated 
nanoparticles. The competitive binding assay confirmed that uptake of targeted nanoparticles 
is through integrin receptors. Enhanced cellular internalization of peptide conjugated 
nanoparticles results in higher cytotoxicity (more than 5 times) of encapsulated CPT than 
plain CPT.  
Induction of apoptosis and generation of ROS are two common mechanisms of action 
for many anticancer drugs.
61-64
 Chromatin condensation and nuclear fragmentation are 
morphological hallmarks of apoptosis.
61 
Induction of apoptosis by the different CPT 
formulations was evaluated by Annexin-V Cys 5.5 and Hoechst nucleus staining assays. In 
both assays, RCPN induces more apoptosis than CPN or non-encapsulated CPT; most likely 
due to enhanced intracellular delivery of drug. Similarly, RCPN treatment results in more 
ROS generation than other formulations. ROS generation causes oxidative stress and kills 
tumor cells through induction of apoptosis.
64 
In wound-healing scratch assays, control or untreated U87MG cells exhibit self-healing 
and migration. RCPN significantly diminishes cell migration, whereas CPN and CPT show 
slight inhibitory activity. The greater inhibition of cell migration by RCPN can be attributed 
to higher anti-angiogenic activity via αvβ3 integrin receptors that are up regulated on vascular 
endothelial cells in tumors.
64 
Conclusions 
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In this study, self-assembled poly(amino acid) based nanoparticles were successfully 
prepared for effective delivery of cytotoxic drug against glioma cells. These nanoparticles 
contain a hydrophobic phenylalanine core and a hydrophilic surface corona of poly(γ-
glutamic acid). Antitumor effects of RCPN are shown by anti-proliferation activity, cell 
morphology and induction of apoptosis. Targeted nanoparticles show higher cellular uptake, 
induced apoptosis through ROS generation and better control over cell migration than non-
targeted nanoparticles. Future research will focus on pharmacokinetic and in vivo tumor 
activity of the prepared formulation using animal models.  
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Executive summary 
• Glioblastoma multiforme (GBM) or grade IV astrocytoma is the most common and 
most aggressive tumor of the glial tumors.  
• Poor physiochemical properties and systemic toxicities limit the efficacy of the 
anticancer drugs against GBM. 
• Poly(γ-glutamic acid)-phenyl alalnine conjugate was synthesized to encapsulate 
camptothecin (CPT) at nanoscale level. 
19 
 
• To improve the specificity towards GBM, nanoparticles were conjugated to cRGDfK 
peptide. 
• Targeted nanoparticles showed significantly higher cytotoxicity against human 
glioblastoma cells than pure CPT. 
• Targeted nanoparticles had time and concentration dependent cytotoxicity.  
• Cellular uptake studies revealed that higher anticancer activity of targeted 
nanoparticles was due to cRGDfK mediated enhanced uptake of nanoparticles.  
• The improved delivery of CPT resulted in reactive oxygen species generation, 
induction of apoptosis and greater control over the migration of glioblastoma cells. 
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Figure legends 
Figure 1. Characterization of nanoparticles: (a) Hydrodynamic diameter of blank poly(γ-
glutamic acid)-phenylalanine nanoparticles (BPN), camptothecin (CPT) loaded poly(γ-
glutamic acid)-phenylalanine nanoparticles (CPN) and cRGDfK conjugated CPN (RCPN). 
(b) FTIR spectra of CPT, CPN, cRGDfK peptide and RCPN. (c) Differential scanning 
calorimetry spectra of CPT and CPN. (d) X-ray diffraction pattern of CPT, PGA-PA, 
physical mixture of CPT and PGA-PA (PM) and CPN. 
 
Figure 2. % Cell viability of U87MG human glioblastoma cells treated with camptothecin 
(CPT), CPT loaded PGA-PA nanoparticles (CPN) or cRGDfK conjugated loaded CPN 
(RCPN), equivalent to 1-400 ng/mL CPT, for (a) 24 h and (b) 48 h. The results are expressed 
as mean ± standard deviation, n = 3.  
 
Figure 3. Cellular uptake of rhodamine-b loaded γ-PGA nanoparticles (RPN) and cRGDfK 
conjugated RPN (RRPN) by U87MG human glioblastoma cells after 2 h of incubation. 
Cellular uptake of RRPN was also studied in the presence of 100 µg/mL cRGDfK. 
 
Figure 4. Apoptosis studies. Apoptosis induced to U87MG human glioblastoma cell after 24 
h treatment with camptothecin (CPT), CPT loaded PGA-PA nanoparticles (CPN) and 
cRGDfK conjugated loaded CPN (RCPN), equivalent to 20 ng/mL CPT, was determined by 
two methods, Hoechst 33342 staining and Annexin-V Cy5.5/PI staining.  (a) Fluorescent 
microscopic images of nucleus of U87MG cells stained with Hoechst 33342 (5 µg/mL) after 
treatment with CPT, CPN or RCPN. (b) Quantitative analysis of the fluorescent microscope 
images (Mean ± SD, n = 3). (c) Percentage of live and apoptotic cells measured using a flow 
cytometer after annexin-V Cy5.5/PI staining (Mean ± SD, n = 3). 
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* represents comparison with control group. (*p < 0.05, **p < 0.01) 
#
 represents comparison with CPT. (
#
p < 0.05, 
## 
p < 0.01) 
 
Figure 5. (a) Qualitative and (b) quantitative determination of reactive oxygen species (ROS) 
generation in U87MG human glioblastoma cell after treatment with camptothecin (CPT), 
CPT loaded PGA-PA nanoparticles (CPN) and cRGDfK conjugated loaded CPN (RCPN). 
Data are presented as Mean ± SD, n = 3. 
* represents comparison with control group. (*p < 0.05, **p < 0.01) 
#
 represents comparison with CPT. (
#
p < 0.05, 
##
 p < 0.01) 
 
Figure 6. Wound healing scratch assay. (a) The wound area in U87MG cells after 0 and 24 h 
of treatment with different formulations. Camptothecin formulations showed inhibition of 
wound healing by decreasing the migration of the cells. (b) Bar graph of wound closure 
obtained with different camptothecin formulations. Inhibition of cell migration was 
significantly greater in cRGDfK peptide conjugated nanoparticles (RCPN; p < 0.01) than 
plain CPT and unconjugated nanoparticles (CPN). Control or untreated cells showed almost 
complete healing of wound after 24 h. Quantitative analysis is an average of six field views. 
* represents comparison with control group. (*p < 0.05, **p < 0.01) 
#
 represents comparison with CPT. (
#
p < 0.05, 
## 
p < 0.01) 
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Figure S1. Chemical synthesis of phenyl alanine ester from phenyl alanine (PA) and then 
conjugation of PAE to poly(-glutamic) acid (PGA) to form PGA-PA conjugate. 
 
 
 
Figure S2. 
1
H NMR spectra of phenylalanine ester (PAE), poly(-glutamic acid) (PGA) and 
poly(-glutamic acid)-phenylalanine conjugate (PGA-PA). 
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Figure S3. a) FTIR spectra of phenyl alanine (PA), phenylalanine ester (PAE), poly(-glutamic 
acid) (PGA) and poly(-glutamic acid)-phenylalanine conjugate (PGA-PA). b) 
Transmission electron microscopic image of PGA-PA nanoparticles. The scale represents 
size in nanometers.  
 
 
 
 
 
 
Figure S4. In vitro release of drug from cRGDfK conjugated, camptothecin loaded PGA-PA 
nanoparticles (RCPN) in phosphate buffer saline (PBS) pH 7.4 and sodium acetate buffer 
(SAB) pH 5. 
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